The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: A multicenter randomized, double-blind, clinical trial (the SPIREN trial)

BMC Nephrology

Volumn 19, Issue 1, 2018, Pages

  Mortensen, Line Aas ^a,b   Thiesson, Helle C ^a,b   Tougaard, Birgitte ^c   Egfjord, Martin ^d   Fischer, Anne Sophie Lind ^e   Bistrup, Claus ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c KOLDING HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Aldosterone; Cyclosporine A; Fibrosis; Glomerular filtration rate; IFTA; Kidney transplantation; Mineralocorticoid; Tacrolimus

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; EDETIC ACID; MINERALOCORTICOID ANTAGONIST; PLACEBO; SPIRONOLACTONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; KIDNEY; PATHOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; TRENDS;

CALCINEURIN INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROSPECTIVE STUDIES; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 85046463589     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-018-0885-6     Document Type: Article

References (35)

1. Calne RY, White DJ, Thiru S, Evans DB, McMaster P, Dunn DC, et al. Cyclosporin a in patients receiving renal allografts from cadaver donors. Lancet. 1978;2:1323-7.
2. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989;2:1000-4.
3. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481-508.
4. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004;78:557-65.
5. Nankivell BJ, P'Ng CH, O'Connell PJ, Chapman JR. Calcineurin inhibitor nephrotoxicity through the Lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. Transplantation. 2016;100:1723-31.
6. Jaisser F, Farman N. Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol Rev. 2016;68:49-75.
7. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013;9:459-69.
8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators. N Engl J Med. 1999;341:709-17.
9. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.
10. Richards AM, Nicholls MG. Aldosterone antagonism in heart failure. Lancet. 1999;354:789-90.
11. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;(4):CD007004. doi: https://doi.org/10.1002/14651858.CD007004.pub3.
12. Perez-Rojas JM, Derive S, Blanco JA, Cruz C, Martinez de la Maza L, Gamba G, et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol. 2005;289:F1020-30.
13. Nielsen FT, Jensen BL, Marcussen N, Skott O, Bie P. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin a nephrotoxicity in conscious rats. Nephrol Dial Transplant. 2008;23:2777-83.
14. McAuley FT, Whiting PH, Thomson AW, Simpson JG. The influence of enalapril or spironolactone on experimental cyclosporin nephrotoxicity. Biochem Pharmacol. 1987;36:699-703.
15. Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine a nephrotoxicity. Kidney Int. 2003;63:43-52.
16. Perez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, et al. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol. 2007;292:F131-9.
17. Macunluoglu B, Arikan H, Atakan A, Tuglular S, Ulfer G, Cakalagaoglu F, et al. Effects of spironolactone in an experimental model of chronic cyclosporine nephrotoxicity. Transplant Proc. 2008;40:273-8.
18. Nielsen FT, Jensen BL, Hansen PB, Marcussen N, Bie P. The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity. BMC Nephrol. 2013;14:42.
19. Medeiros M, Velasquez-Jones L, Hernandez AM, Ramon-Garcia G, Valverde S, Fuentes Y, et al. Randomized controlled trial of mineralocorticoid receptor blockade in children with chronic kidney allograft nephropathy. Clin J Am Soc Nephrol. 2017;12:1291-300.
20. Gonzalez Monte E, Andres A, Polanco N, Toribio MJ, Santana R, Gutierrez Martinez E, et al. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months. Transplant Proc. 2010;42:2899-901.
21. de Sousa MV, Guida JP, do Valle CF, Camargo LF, Rivelli GG, Mazzali M. Spironolactone in post-transplant proteinuria: a safe alternative therapy. Transplant Proc. 2017;49:813-6.
22. Ojeda-Cervantes M, Barrera-Chimal J, Alberu J, Perez-Villalva R, Morales-Buenrostro LE, Bobadilla NA. Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study. Am J Nephrol. 2013;37:481-90.
23. Marcen R, Morales JM, Fernandez-Rodriguez A, Capdevila L, Pallardo L, Plaza JJ, et al. Long-term graft function changes in kidney transplant recipients. NDT Plus. 2010;3:ii2-8.
24. Gill JS, Tonelli M, Mix CH, Pereira BJ. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol. 2003;14:1636-42.
25. Kasiske BL, Gaston RS, Gourishankar S, Halloran PF, Matas AJ, Jeffery J, et al. Long-term deterioration of kidney allograft function. Am J Transplant. 2005;5:1405-14.
26. Gera M, Slezak JM, Rule AD, Larson TS, Stegall MD, Cosio FG. Assessment of changes in kidney allograft function using creatinine-based estimates of glomerular filtration rate. Am J Transplant. 2007;7:880-7.
27. Fleming JS, Zivanovic MA, Blake GM, Burniston M, Cosgriff PS, British Nuclear Medicine S. Guidelines for the measurement of glomerular filtration rate using plasma sampling. Nucl Med Commun. 2004;25:759-69.
28. Ellingsen AR, Nyengaard JR, Osterby R, Jorgensen KA, Petersen SE, Marcussen N. Measurements of cortical interstitium in biopsies from human kidney grafts: how representative and how reproducible? Nephrol Dial Transplant. 2002;17:788-92.
29. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7:684-96.
30. Mortensen LA, Bistrup C, Thiesson HC. Does mineralocorticoid receptor antagonism prevent Calcineurin inhibitor-induced nephrotoxicity? Frontiers in Medicine. 2017;4:210.
31. Mortensen L, Bistrup C, Nielsen FT, Halekoh U, Jensen BL, Marcussen N, et al. The effect of spironolactone on calcineurininhibitor induced nephrotoxicity. Am J transplant journal translated name. Am J Transplant. 2016;16:486.
32. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the randomized Aldactone evaluation study. N Engl J Med. 2004;351:543-51.
33. Bertocchio JP, Barbe C, Lavaud S, Toupance O, Nazeyrollas P, Jaisser F, et al. Safety of Eplerenone for kidney-transplant recipients with impaired renal function and receiving cyclosporine a. PLoS One. 2016;11:e0153635.
34. Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One. 2011;6:e26904.
35. Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (randomized Aldactone evaluation study). J Am Coll Cardiol. 2012;60:2082-9.